ORKA: Oruka Therapeutics, Inc. - Summary | Jitta

Oruka Therapeutics, Inc.

NASDAQ:ORKA

Price
$58.34
Loss Chance
59.1%
n/aJITTA SCORE
100.00%Over Jitta Line
Jitta Ranking
Sorry, the data is not yet available for this stock.
HISTORICAL JITTA SCORE
Sorry, the data is not yet available for this stock.
Jitta Factors
Growth Opportunity (1)
Recent Business Performance (17)
Financial Strength (24)
Return to Shareholders (0)
Competitive Advantage (1)
Jitta Signs
Cash Conversion CycleLess than 30 days
Recent IPOLess than 3 years
Key Stats
Jitta Score
Jitta Line
n/a
100.00%
2.22
136.10%
3.06
202.87%
Biotechnology
5.68
37.62%
5.68
37.62%
4.58
54.88%
COMPANY DESCRIPTION
Oruka Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing novel monoclonal antibody therapeutics for psoriasis (PsO), and other inflammatory and immunology (I&I) indications. Its lead products include ORKA-001 that targets p19 subunit of interleukin-23, which is in phase 2a trial for the treatment of PsO; and ORKA-002 that targets interleukin-17A and interleukin-17F, which is in phase 2 trial for the treatment of PsO, psoriatic arthritis, and other conditions. The company also develops ORKA-003 for targeting an undisclosed pathway; and ORKA-021, a sequential combination regimen of ORKA-002 and ORKA-001. Oruka Therapeutics, Inc. is headquartered in Menlo Park, California.